Cook Children's Health Care System
Cook Children's Health Care System sponsors 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Insulinoma, with 1 trials.
Trial Pipeline
8 total, page 1 of 1
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
NCT06582745
GABA Biomarkers in Dravet Syndrome
NCT05651204
Robot-assisted Training in Children With CP
NCT06450158
Massage Therapy After Thoracic or Lumbar Surgery
NCT06424158
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
NCT02021604
Effect of Ipratropium Bromide on EILO
NCT07394036
Repetitive Transcranial Magnetic Stimulation on Motor Function and Meta-Plasticity in Cerebral Palsy: TMS-EEG Study
NCT07567053
Ex-vivo Confocal Imaging and Proteomic Profiling to Determine Treatment Response in Children With IBD
NCT07121920
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
What the Pipeline for Cook Children's Health Care System Shows
According to the ClinicalTrials.gov registry, Cook Children's Health Care System is linked to 8 US clinical trials across every stage of research activity. Of those, 5 studies are currently recruiting, about 63% of the sponsor's indexed portfolio, and 0 are already marked complete, representing roughly 0% of the total.
The phase mix for Cook Children's Health Care System reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 3 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Cook Children's Health Care System is Insulinoma with 1 linked trial, and 7 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.